文献速递心脑血管急症重症综合管理与镇静镇痛创伤与烧伤

β受体阻滞剂在创伤性颅脑损伤危重患者中的应用:美国创伤外科协会多中心前瞻性观察研究结果

Beta blockers in critically ill patients with traumatic brain injury: Results from a multicenter, prospective, observational American Association for the Surgery of Trauma study.
PubMed 文献 · J Trauma Acute Care Surg · 2018-01-01
一句话结论多中心前瞻性观察显示,创伤性颅脑损伤后使用β受体阻滞剂与较低死亡率相关(校正OR 0.35),普萘洛尔优于其他β受体阻滞剂,支持启动随机对照试验。

美国创伤外科协会临床试验组开展多中心前瞻性观察研究,纳入2015年1月至2017年1月美国与加拿大15个创伤中心需入住ICU的成人创伤性颅脑损伤患者2252例,49.7%接受β受体阻滞剂,56.3%在入院第1天接受首剂。接受β受体阻滞剂者年龄更大(56.7岁 vs 48.6岁,p<0.001)、头部简明损伤定级更高(3.6 vs 3.4,p<0.001)。未校正死亡率较低(13.8% vs 17.7%,p=0.013);多因素回归校正后β受体阻滞剂与较低死亡率相关(校正OR 0.35,p<0.001),普萘洛尔优于其他β受体阻滞剂(校正OR 0.51,p=0.010);Cox回归时间依赖模型显示生存获益(校正HR 0.42,p<0.001),普萘洛尔优于其他β受体阻滞剂(校正HR 0.50,p=0.003)。作者认为该研究为β受体阻滞剂对创伤性颅脑损伤结局的影响提供了有力评估,支持启动多机构随机对照试验。

要点

  • 成人创伤性颅脑损伤需入住ICU者中,接受β受体阻滞剂与较低死亡率相关:未校正13.8% vs 17.7%(p=0.013),校正OR 0.35(p<0.001)。
  • Cox回归时间依赖模型显示β受体阻滞剂与生存获益相关:校正HR 0.42(p<0.001)。
  • 普萘洛尔优于其他β受体阻滞剂:校正OR 0.51(p=0.010),校正HR 0.50(p=0.003)。
  • 接受β受体阻滞剂者年龄更大(56.7岁 vs 48.6岁,p<0.001)、头部简明损伤定级更高(3.6 vs 3.4,p<0.001),校正后获益仍存在。
  • 56.3%的患者在入院第1天接受首剂β受体阻滞剂;作者认为该结果支持启动多机构随机对照试验。

适用人群与场景

  • 美国与加拿大15个创伤中心、需入住ICU的成人创伤性颅脑损伤患者,2015年1月至2017年1月纳入,共2252例。

研究设计与关键结果

  • 研究类型:多中心、前瞻性、观察性研究;样本量2252例;15个创伤中心;人群为需入住ICU的成人创伤性颅脑损伤患者;暴露为β受体阻滞剂使用(49.7%接受),对照为未使用β受体阻滞剂。
  • 接受β受体阻滞剂者年龄更大(56.7岁 vs 48.6岁,p<0.001)、头部简明损伤定级更高(3.6 vs 3.4,p<0.001);性别、入院低血压、平均损伤严重度评分、平均格拉斯哥昏迷评分相似。
  • 未校正死亡率:接受β受体阻滞剂组13.8% vs 未接受组17.7%(p=0.013)。
  • 多因素回归:β受体阻滞剂与较低死亡率相关(校正OR 0.35,p<0.001);普萘洛尔优于其他β受体阻滞剂(校正OR 0.51,p=0.010)。
  • Cox回归时间依赖模型:β受体阻滞剂与生存获益相关(校正HR 0.42,p<0.001);普萘洛尔优于其他β受体阻滞剂(校正HR 0.50,p=0.003)。
  • 56.3%的患者在入院第1天接受首剂β受体阻滞剂。

证据类型、等级与局限

  • 证据类型:多中心前瞻性观察性研究;证据等级:治疗/医疗管理,level III。
  • 局限:原文未报告局限性。

对床旁实践的改变

  • 作者认为,创伤性颅脑损伤后使用β受体阻滞剂与改善生存相关,且在校正治疗队列中更严重损伤后仍存在,该研究为β受体阻滞剂对创伤性颅脑损伤结局的影响提供了有力评估,支持启动多机构随机对照试验。

提炼说明

  • 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「处置流程与药物剂量」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开

BACKGROUND: Beta blockers, a class of medications that inhibit endogenous catecholamines interaction with beta adrenergic receptors, are often administered to patients hospitalized after traumatic brain injury (TBI). We tested the hypothesis that beta blocker use after TBI is associated with lower mortality, and secondarily compared propranolol to other beta blockers.

METHODS: The American Association for the Surgery of Trauma Clinical Trial Group conducted a multi-institutional, prospective, observational trial in which adult TBI patients who required intensive care unit admission were compared based on beta blocker administration.

RESULTS: From January 2015 to January 2017, 2,252 patients were analyzed from 15 trauma centers in the United States and Canada with 49.7% receiving beta blockers. Most patients (56.3%) received the first beta blocker dose by hospital day 1. Those patients who received beta blockers were older (56.7 years vs. 48.6 years, p < 0.001) and had higher head Abbreviated Injury Scale scores (3.6 vs. 3.4, p < 0.001). Similarities were noted when comparing sex, admission hypotension, mean Injury Severity Score, and mean Glasgow Coma Scale. Unadjusted mortality was lower for patients receiving beta blockers (13.8% vs. 17.7%, p = 0.013). Multivariable regression determined that beta blockers were associated with lower mortality (adjusted odds ratio, 0.35; p < 0.001), and propranolol was superior to other beta blockers (adjusted odds ratio, 0.51, p = 0.010). A Cox-regression model using a time-dependent variable demonstrated a survival benefit for patients receiving beta blockers (adjusted hazard ratio, 0.42, p < 0.001) and propranolol was superior to other beta blockers (adjusted hazard ratio, 0.50, p = 0.003).

CONCLUSION: Administration of beta blockers after TBI was associated with improved survival, before and after adjusting for the more severe injuries observed in the treatment cohort. This study provides a robust evaluation of the effects of beta blockers on TBI outcomes that supports the initiation of a multi-institutional randomized control trial.

LEVEL OF EVIDENCE: Therapeutic/care management, level III.

来源:J Trauma Acute Care Surg,查看原文。版权归原作者所有。

参考来源

  1. Ley EJ, Leonard SD, Barmparas G, et al. Beta blockers in critically ill patients with traumatic brain injury: Results from a multicenter, prospective, observational American Association for the Surgery of Trauma study. J Trauma Acute Care Surg. 2018. PMID: 29251711. doi:10.1097/TA.0000000000001747

供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。